肿瘤细胞治疗研究
ALL SOURCES
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinica
采用TBI-1301过继性免疫疗法选择性靶向NY-ESO-1阳性肿瘤细胞，似乎是治疗晚期或复发性SS的一种有前景的策略，且毒性可接受。
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
该试验显示，内源性 TCR 沉默且亲和力增强的 NY-ESO-1 TCR-T 细胞可安全给药，除 3 级肺损伤外。
Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes.
免疫逃逸是成功实现肿瘤免疫治疗的主要障碍。
Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy.
靶向 NY-ESO-1 和 MAGE-A4 的 TCR 工程化 T 细胞治疗已开展临床试验，多项试验报告的客观缓解率为 40-60%。
Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes.
肿瘤免疫治疗是靶向 ARID1A 缺陷型卵巢透明细胞癌的一种有效方法。
Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor
艾日布林通过 HLA 1 类反式激活因子 NLRC5 增加 HLA 1 类的表达，艾日布林与免疫治疗联合可有效治疗乳腺癌。
T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host
使用基因工程改造的患者来源淋巴细胞来表达肿瘤反应性受体的过继性免疫疗法是一种有前景的恶性肿瘤治疗方法。
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatm
不经淋巴细胞清除的 NY-ESO-1 特异性 TCR-T 细胞疗法联合携带含 NY-ESO-1 表位的 LPA 的普鲁兰纳米凝胶疫苗接种是可行的，并可在难治性 SS 中诱导有前景的持久疗效（注册号：JMA-IIA00346）。
Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The pr
T-iPSCs有潜力成为提供细胞毒性TCs的无限细胞来源。
Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
这些数据表明aAVC-NY-ESO-1具有利用固有免疫和适应性免疫对抗表达NY-ESO-1的恶性肿瘤的潜力。
MEMBER ACCOUNT
登录成功会直接打开下一页。
